NDAORALCAPSULE
Approved
Oct 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ACHROMYCIN V (tetracycline hydrochloride) by Pfizer is clinical pharmacology tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. Approved for bacterial vaginosis, vulvovaginal candidiasis. First approved in 1957.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACHROMYCIN V (Tetracycline Hydrochloride) is a broad-spectrum oral antibiotic approved in 1957 that treats bacterial vaginosis and vulvovaginal candidiasis. It works by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, making it bacteriostatic against gram-positive and gram-negative organisms. The drug is indicated for patients with documented vaginal infections requiring oral antimicrobial therapy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating reduced team expansion and focus on cost management and market share defense.
Mechanism of Action
CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Microbiology Tetracyclines are primarily…
Indications (2)
Worked on ACHROMYCIN V at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.